GLO1 and schizophrenia: Considering the molecular mechanism revealed in this study, GLO1 inducers, such as trans-resveratrol and hesperatin [79], rather than inhibitors and VB6 supplementation [80] may be effective as a new therapeutic strategy for schizophrenia patients with GLO1 dysfunction and VB6 deficiency.